Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2026-05-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 75% confidence The document is an announcement (“公告”) by a listed company on the progress of using idle raised funds (“闲置募集资金进行现金管理的进展公告”). It details amounts invested, redemption status, risk controls, and account terminations for cash management of fundraising proceeds. It does not contain financial statements or serve as a general report publication notice, but rather provides an update on how the company’s fundraising proceeds are being managed, which falls under updates on financing activities. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-05-25 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2025年度持续督导定期现场检查报告
Audit Report / Information Classification · 80% confidence The document is a detailed onsite inspection report (“现场检查报告”) prepared by the sponsor (中信证券) for the ongoing supervision of a listed company, covering governance, internal control, disclosure, use of funds, performance checks, etc. It is not a simple announcement or a summary; it is the full supervisory/audit‐style report itself. This aligns with the Audit Report / Information category (AR) for standalone audit or regulatory inspection reports outside of full annual/quarterly filings. FY 2025
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2025年度保荐工作报告
Regulatory Filings Classification · 45% confidence The document is a 2025 annual sponsorship work report (“保荐工作报告”) prepared by the sponsor (CITIC Securities) on its regulatory review, supervision, and compliance actions for Jinling Pharmaceutical. This is not an earnings release, annual report, management discussion, proxy statement, or other specific category. It is a required regulatory submission by the sponsor but does not match any narrowly defined filing type. Hence it defaults to the general Regulatory Filings category.
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年向特定对象发行股票持续督导保荐总结报告书
Share Issue/Capital Change Classification · 80% confidence The document is a detailed sponsor (保荐人) summary report (“持续督导保荐总结报告书”) concerning Jinling Pharmaceutical’s 2023 directed A-share issuance: it spells out the number of shares, issue price, net proceeds, regulatory approvals and continuous supervision work. This falls under share issuance/capital change filings rather than an earnings release, management discussion, or annual report. Therefore the best fit is Share Issue/Capital Change (SHA).
2026-04-14 Chinese
金陵药业股份有限公司第九届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 24th meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, and voting results on various reports and proposals such as the 2025 President's Work Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Self-Evaluation Report, and others. It also references that the detailed reports and documents are published on a designated website and newspapers on March 31, 2026. The document itself is a formal announcement of board meeting decisions rather than the full reports or financial statements. The length is 3756 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2026-03-30 Chinese
2025年年度审计报告
Audit Report / Information Classification · 98% confidence The document is a full standalone audit report issued by a licensed accounting firm (立信会计师事务所) including the auditor’s opinion, key audit matters, auditor’s responsibilities, and the complete set of consolidated and parent financial statements with notes for the year ended December 31, 2025. It is not merely an announcement or proxy material but a full audit opinion and related financial statements. This matches the definition of an Audit Report / Information filing. FY 2025
2026-03-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.